NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date (Descending) | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
63187-0085-21 | 63187-0085 | Prednisone | Prednisone | 20.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Nov. 1, 2018 | In Use | |
63187-0085-24 | 63187-0085 | Prednisone | Prednisone | 20.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Nov. 1, 2018 | In Use | |
63187-0085-30 | 63187-0085 | Prednisone | Prednisone | 20.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Nov. 1, 2018 | In Use | |
63187-0160-21 | 63187-0160 | Methylprednisolone | Methylprednisolone | 4.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Nov. 1, 2018 | In Use | |
63187-0002-10 | 63187-0002 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Nov. 1, 2018 | In Use | |
63187-0002-15 | 63187-0002 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Nov. 1, 2018 | In Use | |
63187-0002-20 | 63187-0002 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Nov. 1, 2018 | In Use | |
63187-0002-30 | 63187-0002 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Nov. 1, 2018 | In Use | |
63187-0483-10 | 63187-0483 | Ondansetron | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Nov. 1, 2018 | In Use | |
63187-0483-15 | 63187-0483 | Ondansetron | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Nov. 1, 2018 | In Use | |
63187-0483-20 | 63187-0483 | Ondansetron | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Nov. 1, 2018 | In Use | |
69639-0103-01 | 69639-0103 | Palonosetron hydrochloride | Aloxi | 0.05 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intravenous | Nov. 1, 2018 | Nov. 1, 2022 | No Longer Used |
69639-0103-05 | 69639-0103 | Palonosetron hydrochloride | Aloxi | 0.05 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intravenous | Nov. 1, 2018 | Nov. 1, 2022 | No Longer Used |
63187-0080-30 | 63187-0080 | Anastrozole | Anastrozole | 1.0 mg/1 | Hormonal Therapy | Aromatase Inhibitor | Oral | Nov. 1, 2018 | In Use | ||
50419-0385-72 | 50419-0385 | Copanlisib | Aliqopa | 15.0 mg/mL | Chemotherapy | Enzyme Inhibitor | PI3K | Intravenous | Oct. 30, 2018 | In Use | |
50090-0167-00 | 50090-0167 | Estrogens, Conjugated | Premarin | 0.625 mg/1 | Hormonal Therapy | Estrogen | Oral | Oct. 29, 2018 | In Use | ||
70518-0473-02 | 70518-0473 | Prednisone | Prednisone | 10.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Oct. 29, 2018 | In Use | |
50742-0405-10 | 50742-0405 | Oxaliplatin | Oxaliplatin | 50.0 mg/10mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | Oct. 29, 2018 | In Use | |
50742-0406-20 | 50742-0406 | Oxaliplatin | Oxaliplatin | 100.0 mg/20mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | Oct. 29, 2018 | In Use | |
00069-0296-30 | 00069-0296 | talazoparib | Talzenna | 0.25 mg/1 | Chemotherapy | Enzyme Inhibitor | PARP | Oral | Oct. 26, 2018 | In Use | |
00069-1195-30 | 00069-1195 | talazoparib | Talzenna | 1.0 mg/1 | Chemotherapy | Enzyme Inhibitor | PARP | Oral | Oct. 26, 2018 | In Use | |
46014-0296-01 | 46014-0296 | talazoparib | Talzenna | 0.25 mg/1 | Chemotherapy | Enzyme Inhibitor | PARP | Oral | Oct. 26, 2018 | In Use | |
46014-1195-03 | 46014-1195 | talazoparib | Talzenna | 1.0 mg/1 | Chemotherapy | Enzyme Inhibitor | PARP | Oral | Oct. 26, 2018 | In Use | |
00310-4715-11 | 00310-4715 | IV Solution Stabilizer for Lumoxiti | IV Solution Stabilizer for Lumoxiti | 6.5 mg/mL | Ancillary Therapy | Excipient | Intravenous | Oct. 24, 2018 | In Use | ||
51655-0415-87 | 51655-0415 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Oct. 24, 2018 | In Use |
Found 10,000 results in 6 milliseconds — Export these results